Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novo Nordisk ASWBO:NNO2 -2.03%80 Gross-Profit-to-Asset % is 42.54% as of Jun. 2026. GuruFocus rates WBO:NNO2 with a GF Score™ of 80/100 and a GF Value™ of €93.42 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 957 Drug Manufacturers companies, Novo Nordisk AS ranks better than 86.1% on this metric.
Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Novo Nordisk AS's annualizedGross Profit for the quarter that ended in Jun. 2026 was €32,840 Mil.
Novo Nordisk AS's average Total Assets over the quarter that ended in Jun. 2026 was €77,193 Mil. Therefore, Novo Nordisk AS's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2026 was 42.54%.
Novo Nordisk AS Gross-Profit-to-Asset % Related Terms
Novo Nordisk AS Gross-Profit-to-Asset % Historical Data
* Premium members only.
The historical data trend for Novo Nordisk AS's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:NNO2 vs LLY, JNJ, ABBV: Gross-Profit-to-Asset % Comparison
For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novo Nordisk AS Gross-Profit-to-Asset % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where Novo Nordisk AS's Gross-Profit-to-Asset % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Jun. 2026) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
What does a Gross-Profit-to-Asset % of 42.54% mean?
Novo Nordisk AS (WBO:NNO2) has a Gross-Profit-to-Asset % of 42.54% as of Jun. 2026. Gross Profit to Asset Ratio is the total gross profit divided by total assets. View historical data on Novo Nordisk AS and its competitors. According to the industry distribution chart, Novo Nordisk AS ranks #133 out of 957 companies in the Drug Manufacturers industry, placing it in the top 13.9%.
Is Novo Nordisk AS's Gross-Profit-to-Asset % too high?
Novo Nordisk AS's current Gross-Profit-to-Asset % is 42.54%. The Drug Manufacturers industry median Gross-Profit-to-Asset % is 24.98. Novo Nordisk AS's value of 42.54% is 70.3% above this industry median. Based on the distribution chart, Novo Nordisk AS ranks #133 out of 957 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Novo Nordisk AS has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Gross-Profit-to-Asset % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novo Nordisk AS ranks #133 out of 957 companies for Gross-Profit-to-Asset %. This places Novo Nordisk AS in the top 14% of its industry — outperforming the majority of peers. The industry median Gross-Profit-to-Asset % is 24.98. Novo Nordisk AS's value of 42.54% is 70.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross-Profit-to-Asset % for a Drug Manufacturers company?
The median Gross-Profit-to-Asset % among Drug Manufacturers companies is 24.98, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a Gross-Profit-to-Asset % significantly above this median, while those in the bottom quartile fall well below. However, Gross-Profit-to-Asset % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novo Nordisk AS's current Gross-Profit-to-Asset % of 42.54% is 70.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross-Profit-to-Asset % mean?
A high Gross-Profit-to-Asset % can signal that a stock is expensive relative to its fundamentals. Gross Profit to Asset Ratio is the total gross profit divided by total assets. View historical data on Novo Nordisk AS and its competitors. For the Drug Manufacturers industry, the median Gross-Profit-to-Asset % is 24.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novo Nordisk AS's current Gross-Profit-to-Asset % is 42.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (WBO:NNO2) is currently considered Significantly Undervalued. The stock's GF Value™ is €93.42, compared to a current price of €40.86 — trading 56.3% below its estimated fair value. The current Gross-Profit-to-Asset % is 42.54% and 70.3% above the Drug Manufacturers industry median of 24.98. Novo Nordisk AS's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross-Profit-to-Asset % calculated?
Gross-Profit-to-Asset % is calculated from a company's financial statements. For Novo Nordisk AS (WBO:NNO2), the current Gross-Profit-to-Asset % is 42.54% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novo Nordisk AS (WBO:NNO2) Overvalued in 2026?
Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued.
The current stock price of €40.86 is trading 56.3% below its estimated GF Value™ of €93.42.
GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.
Key valuation signals for WBO:NNO2:
Gross-Profit-to-Asset %: 42.54%
GF Value™: €93.42 vs. price of €40.86 (56.3% below fair value)
Industry Position: 70.3% above the Drug Manufacturers median (#133 of 957)
No single metric tells the full story. See the WBO:NNO2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
80GF Score
Get the complete analysis for WBO:NNO2
Gross-Profit-to-Asset % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:NNO2 has been successfully added to your 
